Avation Medical Secures Funding for U.S. Launch
Grace Mahas — February 2, 2024 — Lifestyle
References: avation & tdpelmedia
Avation Medical has announced a significant milestone in securing funding for the U.S. launch of its innovative Vivally System, a wearable neuromodulation system designed to address urge urinary incontinence and urinary urgency associated with Overactive Bladder (OAB) syndrome. The Vivally System offers a groundbreaking approach to bladder control therapy, allowing patients to undergo effective neuromodulation therapy at home without the need for surgery, implants, or pharmaceuticals. This smart, wearable device, complemented by a supportive mobile app, represents a leap forward in patient-centered care, providing a non-invasive, convenient, and personalized treatment option.
The recent funding round saw contributions from a diverse group of investors including ShangBay Capital, Asahi Kasei, Angelini Ventures, JobsOhio Growth Capital Fund, Arboretum Ventures, Tonkawa, Medtronic, and Avestria Ventures. This broad investor support underscores the promising potential of Avation Medical's technology to revolutionize the management of OAB syndrome.
The recent funding round saw contributions from a diverse group of investors including ShangBay Capital, Asahi Kasei, Angelini Ventures, JobsOhio Growth Capital Fund, Arboretum Ventures, Tonkawa, Medtronic, and Avestria Ventures. This broad investor support underscores the promising potential of Avation Medical's technology to revolutionize the management of OAB syndrome.
Trend Themes
1. Wearable Neuromodulation Systems - The Vivally System offers a groundbreaking approach to bladder control therapy, allowing patients to undergo effective neuromodulation therapy at home without the need for surgery, implants, or pharmaceuticals.
2. Patient-centered Care - This smart, wearable device, complemented by a supportive mobile app, represents a leap forward in patient-centered care, providing a non-invasive, convenient, and personalized treatment option.
3. Revolutionizing OAB Syndrome Management - The promising potential of Avation Medical's technology to revolutionize the management of OAB syndrome is underscored by the broad investor support in the recent funding round.
Industry Implications
1. Healthcare - Avation Medical's Vivally System disrupts traditional bladder control therapy methods, offering a wearable neuromodulation system that provides a non-invasive and personalized treatment option.
2. Medical Devices - The Vivally System by Avation Medical represents a disruptive innovation in the field of medical devices, revolutionizing the management of Overactive Bladder (OAB) syndrome.
3. Digital Health - The integration of a supportive mobile app with Avation Medical's Vivally System highlights the disruptive potential of digital health in providing patient-centered care for OAB syndrome.
5
Score
Popularity
Activity
Freshness
